News >

Acalabrutinib Triplet Impresses in Frontline CLL, Advances to Phase III Study

Caroline Seymour
Published: Tuesday, Apr 07, 2020

Benjamin L. Lampson, MD, PhD, medical oncologist at Dana-Farber Cancer Institute

Benjamin L. Lampson, MD, PhD

The addition of acalabrutinib (Calquence) to the combination of venetoclax (Venclexta) and obinutuzumab (Gazyva) was shown to be highly active in patients with newly diagnosed chronic lymphocytic leukemia (CLL), eliciting deep and durable responses that improved over time, according to data from a phase II trial (NCT03580928).
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication